Furthermore, since a combination of immunotherapy and antineoangiogenetic therapy are the standard of care in metastatic ccRCC [17,18,19], PSMA-targeted PET/CT might be a valuable tool to anticipate the treatment’s outcome and to assess the response to therapies in ccRCC patients. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.